{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:54:06Z","timestamp":1756385646289},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sunitinib-induced high-grade proteinuria and irreversible renal allograft dysfunction are rare conditions. Here, we present a patient who had received renal allograft and later developed metastatic clear cell renal cell carcinoma(cc-mRCC), for which he was prescribed sunitinib. High-grade proteinuria, hypoalbuminemia, peripheral edema and renal allograft dysfunction (manifesting as an increase in the serum creatinine concentration) occurred 5\u2009months after sunitinib prescription.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The patient was a 58-year-old male who had end-stage renal disease with regular hemodialysis through arteriovenous fistula for 17\u2009years since 1998 and received a renal allograft from a deceased kidney donor in 2015. Unfortunately, in 2019, the patient developed cc-mRCC originating from the left native kidney. We suggested a needle biopsy on left native kidney or radical left nephrectomy, but the patient refused. Sunitinib was prescribed. Follow-up urine analysis showed proteinuria (500\u2009mg\/dL) 2 weeks after sunitinib prescription. He was hospitalized 5\u2009months later because of body weight gain, decreased urine output, pitting edema of both lower extremities, and shortness of breath. The image studies showed progression in his cc-mRCC. His serum creatinine level and spot urine protein at admission increased to 4.26\u2009mg\/dL and 300\u2009mg\/dL, respectively. He agreed on a biopsy for the renal allograft and the pathology studies showed focal segmental glomerulosclerosis, acute interstitial nephritis, and acute tubular injury. Based on the time sequence of clinical presentations with the laboratory and pathological findings, sunitinib-induced renal allograft dysfunction secondary to high-grade proteinuria was most likely. Despite of discontinuation of sunitinib and increased dose of everolimus, renal impairment progressed. Thus, he had to receive hemodialysis starting 2 week after hospitalization. Unfortunately, the patient died of advanced metastasis despite of aggressive medical treatments 3\u2009weeks after admission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case report is a reminder that renal allograft dysfunction can happen secondary to proteinuria after taking sunitinib. Hence, clinicians must regularly check renal function and urine protein for renal allograft recipients. Monitoring and modifying drug prescription, especially sunitinib, is necessary if persistent proteinuria accompanied by deteriorating serum creatinine level occurs. Renal biopsy may be considered if more evidence is required to make a differential diagnosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02789-5","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T08:02:41Z","timestamp":1650268961000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Hsu-Cheng","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Pao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiann-Der","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Huang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Te","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong-Chin","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"2789_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000241551","volume":"2","author":"YS Chen","year":"2009","unstructured":"Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol. 2009;2:172\u20136.","journal-title":"Case Rep Oncol"},{"key":"2789_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/jjco\/hyr140","volume":"41","author":"YC Liu","year":"2011","unstructured":"Liu YC, Chang PMH, Liu CY, Yang CY, Chen MH, Pan CC, et al. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Jpn J Clin Oncol. 2011;41:1277\u201381.","journal-title":"Jpn J Clin Oncol."},{"key":"2789_CR3","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1111\/ajt.13862","volume":"16","author":"S Karami","year":"2016","unstructured":"Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, et al. Risk of renal cell carcinoma among kidney transplant recipients in the United States. Am J Transplant. 2016;16:3479\u201389.","journal-title":"Am J Transplant."},{"key":"2789_CR4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/jcm8040530","volume":"8","author":"A Chewcharat","year":"2019","unstructured":"Chewcharat A, Thongprayoon C, Bathini T, Aeddula NR, Boonpheng B, Kaewput W, et al. Incidence and mortality of renal cell carcinoma after kidney transplantation: A meta-analysis. J Clin Med. 2019;8:530.","journal-title":"J Clin Med."},{"key":"2789_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bju.13185","volume":"117","author":"S Kalra","year":"2016","unstructured":"Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016;117:761\u20135.","journal-title":"BJU Int."},{"key":"2789_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107\u201313.","journal-title":"Oncologist."},{"key":"2789_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061\u20138.","journal-title":"J Clin Oncol."},{"issue":"21","key":"2789_CR8","first-page":"00322","volume":"S0302-2838","author":"J Bedke","year":"2021","unstructured":"Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, et al. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol. 2021;S0302-2838(21):00322\u20135.","journal-title":"Eur Urol."},{"key":"2789_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med."},{"key":"2789_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djm311","volume":"100","author":"TV Patel","year":"2008","unstructured":"Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282\u20134.","journal-title":"J Natl Cancer Inst."},{"key":"2789_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","volume":"29","author":"C Vigneau","year":"2014","unstructured":"Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, et al. All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study. Nephrol Dial Transplant. 2014;29:325\u201332.","journal-title":"Nephrol Dial Transplant."},{"key":"2789_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, et al. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med. 2014;29:40\u20138.","journal-title":"Korean J Intern Med."},{"key":"2789_CR13","first-page":"267","volume":"70","author":"ES den Deurwaarder","year":"2012","unstructured":"den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen CM. Kidney injury during VEGF inhibitor therapy. Neth J Med. 2012;70:267\u201371.","journal-title":"Neth J Med."},{"key":"2789_CR14","doi-asserted-by":"publisher","first-page":"143426","DOI":"10.1155\/2014\/143426","volume":"2014","author":"H Izzedine","year":"2014","unstructured":"Izzedine H. Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol. 2014;2014:143426.","journal-title":"Int J Nephrol."},{"issue":"4","key":"2789_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","volume":"14","author":"SR Hayman","year":"2012","unstructured":"Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285\u201394.","journal-title":"Curr Oncol Rep."},{"issue":"25","key":"2789_CR16","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","volume":"32","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765\u201372.","journal-title":"J Clin Oncol."},{"issue":"15","key":"2789_CR17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382.","journal-title":"Lancet Oncol."},{"key":"2789_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1200\/JCO.2021.39.6_suppl.307","volume":"39","author":"SK Pal","year":"2021","unstructured":"Pal SK, Puente J, Heng DYC, et al. PhaseIItrial oflenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI). J Clin Oncol. 2021;39:307.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2789_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/ctr.12357","volume":"28","author":"GB Klintmalm","year":"2014","unstructured":"Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant. 2014;28(6):635\u201348.","journal-title":"Clin Transplant."},{"issue":"9","key":"2789_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/ckj\/sfaa262","volume":"14","author":"MG Naik","year":"2020","unstructured":"Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, et al. Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J. 2020;14(9):2047\u201358.","journal-title":"Clin Kidney J."},{"issue":"19","key":"2789_CR21","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1056\/NEJM200511103531922","volume":"353","author":"H Izzedine","year":"2005","unstructured":"Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med. 2005;353(19):2088\u20139.","journal-title":"N Engl J Med."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02789-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T11:10:12Z","timestamp":1650366612000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02789-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2789"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02789-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This report has been approved by the Institutional Review Board of Ditmanson Medical Foundation Chia-Yi Christian Hospital (approval number: CYCH-IRB-20210-11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained in written format from next of kin of the patient to publish this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No authors have any competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}